Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	APR 02	CAS Registry Number Crossover Limits Increased to 500,000 in Key STN Databases
NEWS 3	APR 02	PATDPAFULL: Application and priority number formats enhanced
NEWS 4	APR 02	DWPI: New display format ALLSTR available
NEWS 5	APR 02	New Thesaurus Added to Derwent Databases for Smooth Sailing through U.S. Patent Codes
NEWS 6	APR 02	EMBASE Adds Unique Records from MEDLINE, Expanding Coverage back to 1948
NEWS 7	APR 07	CA/CAplus CLASS Display Streamlined with Removal of Pre-IPC 8 Data Fields
NEWS 8	APR 07	50,000 World Traditional Medicine (WTM) Patents Now Available in CAplus
NEWS 9	APR 07	MEDLINE Coverage Is Extended Back to 1947
NEWS 10	JUN 16	WPI First View (File WPIFV) will no longer be available after July 30, 2010
NEWS 11	JUN 18	DWPI: New coverage - French Granted Patents
NEWS 12	JUN 18	CAS and FIZ Karlsruhe announce plans for a new STN platform
NEWS 13	JUN 18	IPC codes have been added to the INSPEC backfile (1969-2009)
NEWS 14	JUN 21	Removal of Pre-IPC 8 data fields streamline displays in CA/CAplus, CASREACT,and MARPAT
NEWS 15	JUN 21	Access an additional 1.8 million records exclusively enhanced with 1.9 million CAS Registry Numbers -- EMBASE Classic on STN
NEWS 16	JUN 28	Introducing "CAS Chemistry Research Report": 40 Years of Biofuel Research Reveal China Now Atop U.S. in Patenting and Commercialization of Bioethanol
NEWS 17	JUN 29	Enhanced Batch Search Options in DGENE, USGENE, and PCTGEN
NEWS 18	JUL 19	Enhancement of citation information in INPADOC databases provides new, more efficient competitor analyses

NEWS EXPRESS FEBRUARY 15 10 CURRENT WINDOWS VERSION IS V8.4.2,
AND CURRENT DISCOVER FILE IS DATED 15 JANUARY 2010.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 05:36:01 ON 26 JUL 2010

=> file reg
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 0.22 0.22

FILE 'REGISTRY' ENTERED AT 05:36:20 ON 26 JUL 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 23 JUL 2010 HIGHEST RN 1233764-64-1
DICTIONARY FILE UPDATES: 23 JUL 2010 HIGHEST RN 1233764-64-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 8, 2010.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> logoff hold
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 0.49 0.71

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 05:36:26 ON 26 JUL 2010

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:
* * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'REGISTRY' AT 05:39:11 ON 26 JUL 2010
FILE 'REGISTRY' ENTERED AT 05:39:11 ON 26 JUL 2010
COPYRIGHT (C) 2010 American Chemical Society (ACS)

COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION

FULL ESTIMATED COST 0.49 0.71

=>
Uploading C:\Documents and Settings\PZucker\My Documents\Examination Auxillary files\10589410\10589410 1 st chosen specie.str

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> search l1 sss sam
SAMPLE SEARCH INITIATED 05:39:58 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 54 TO ITERATE

100.0% PROCESSED 54 ITERATIONS 19 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 640 TO 1520
PROJECTED ANSWERS: 119 TO 641

L2 19 SEA SSS SAM L1

=> d scan

L2 19 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Glycine, N-(2,6-difluorobenzoyl)-N-[4'-(1-methylethyl)[1,1'-biphenyl]-3-yl]-, 1,1-dimethylethyl ester
MF C28 H29 F2 N O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):5

L2 19 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Glycine, N-(2,6-dimethylbenzoyl)-N-[3-(methylthio)phenyl]-, 1,1-dimethylethyl ester
MF C22 H27 N O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 19 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Glycine, N-(5-chloro-2-methoxyphenyl)-N-(2,4,6-trifluorobenzoyl)-, 1,1-dimethylethyl ester
MF C20 H19 Cl F3 N O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 19 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Glycine, N-[3-(1H-pyrazol-3-yl)phenyl]-N-(2,4,6-trichlorobenzoyl)-, 1,1-dimethylethyl ester
MF C22 H20 Cl3 N3 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 19 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Glycine, N-(2,6-difluorobenzoyl)-N-(4'-methoxy-3'-methyl[1,1'-biphenyl]-3-yl)-, 1,1-dimethylethyl ester
MF C27 H27 F2 N O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 19 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Glycine, N-(4'-hydroxy[1,1'-biphenyl]-3-yl)-N-(2,4,6-trifluorobenzoyl)-, 1,1-dimethylethyl ester
MF C25 H22 F3 N O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> full
ENTER LOGIC EXPRESSION, QUERY NAME, OR (END):end
SEARCH ENDED BY USER

=> search l1 sss full
FULL SEARCH INITIATED 05:40:46 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1078 TO ITERATE

100.0% PROCESSED 1078 ITERATIONS 327 ANSWERS
SEARCH TIME: 00.00.01

L3 327 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	192.52	192.74

FILE 'CAPLUS' ENTERED AT 05:41:06 ON 26 JUL 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 26 Jul 2010 VOL 153 ISS 5
FILE LAST UPDATED: 25 Jul 2010 (20100725/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Apr 2010
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Apr 2010

CAplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2010.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> l3
L4 8 L3

=> d l8 1-08 ti
L8 NOT FOUND
The L-number entered has not been defined in this session, or it has been deleted. To see the L-numbers currently defined in this session, enter DISPLAY HISTORY at an arrow prompt (=>).

=> d l4 1-8 ti

L4 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2010 ACS on STN
TI Preparation of phenylpyrimidinones as HSP90 inhibitors for treating and preventing hyperproliferative diseases

L4 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2010 ACS on STN
TI Salicylanilides: Selective inhibitors of interleukin-12p40 production

L4 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2010 ACS on STN
TI Identification of 14-3-3ζ by Chemical Affinity with Salicylanilide Inhibitors of Interleukin-12p40 Production

L4 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2010 ACS on STN
TI Preparation of heterocyclic condensed compounds useful as antidiuretic agents

L4 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2010 ACS on STN
TI Compounds and compositions as LXR modulators

L4 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2010 ACS on STN
TI Preparation of 2-[(carbamoylmethyl)carbamoyl]phenylpropanoates and analogs as αvβ3 integrin receptor ligands

L4 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2010 ACS on STN
TI Preparation of guanidinophenol derivatives as phospholipase and trypsin inhibitors

L4 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2010 ACS on STN
TI Benzoylglycine derivatives as herbicides and their preparation

```
=> d l4 1-8 ti fbib abs

L4   ANSWER 1 OF 8  CAPLUS  COPYRIGHT 2010 ACS on STN
TI   Preparation of phenylpyrimidinones as HSP90 inhibitors for treating and
     preventing hyperproliferative diseases
AN   2008:1188201  CAPLUS <<LOGINID::20100726>>
DN   149:425970
TI   Preparation of phenylpyrimidinones as HSP90 inhibitors for treating and
     preventing hyperproliferative diseases
IN   Lee, Chi-Wan; Przewloka, Teresa; Ying, Weiwen; Song, Minghu; Du, Zhenjian;
     Foley, Kevin; Zhou, Dan; Qin, Shuzhen
PA   Synta Pharmaceuticals Corp., USA
SO   PCT Int. Appl., 160pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ---------------     ----   --------    --------------------   --------
PI   WO 2008118391        A2    20081002    WO 2008-US3810         20080324
     WO 2008118391        A3    20081218
         W:  AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
             CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES,
             FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE,
             KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
             ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,
             PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM,
             TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
             IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,
             TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
             TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
             AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
                                             US 2007-920327P    P  20070327
     AU 2008232354        A1    20081002    AU 2008-232354        20080324
                                             US 2007-920327P    P  20070327
                                             WO 2008-US3810     W  20080324
     CA 2682665           A1    20081002    CA 2008-2682665       20080324
                                             US 2007-920327P    P  20070327
                                             WO 2008-US3810     W  20080324
     EP 2155694           A2    20100224    EP 2008-742209        20080324
         R:  AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
             IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI,
             SK, TR, AL, BA, MK, RS
                                             US 2007-920327P    P  20070327
                                             WO 2008-US3810     W  20080324
     JP 2010522750        T     20100708    JP 2010-500949        20080324
                                             US 2007-920327P    P  20070327
                                             WO 2008-US3810     W  20080324
OS   MARPAT 149:425970
GI
```



I



II



III



IV

AB The present invention relates to compds. I-IV [R2, R3 = NR7H, OR7, SR7, etc.; R4 = (un)substituted alkyl, cycloalkyl, aryl, etc.; R7 = H, alkyl, cycloalkyl, etc.; R14, R15 = H, C(O)R7, C(O)OR7, etc.] and their compns. that inhibit the activity of Hsp90. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a compound I-IV, or a composition comprising such a compound I-IV.
Preparation of five compds. I-IV is described. Thus, reacting Et acetoacetate with 2,4-bis(benzyloxy)-5-isopropylbenzaldehyde and urea in the presence of concentrate HCl in EtOH followed by hydrogenation of the resulting intermediate afforded I [R2, R4 = OH; R4 = iso-Pr; R14 = CO2Et; R15 = Me] which showed IC50 of >100 μM when tested for inhibition of Hsp90. Pharmaceutical compns. comprising the compound I-IV alone or in combination with other therapeutic agent, were disclosed.
OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

L4 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2010 ACS on STN
TI Salicylanilides: Selective inhibitors of interleukin-12p40 production
AN 2008:1124691 CAPLUS <<LOGINID::20100726>>
DN 149:548243
TI Salicylanilides: Selective inhibitors of interleukin-12p40 production
AU Brown, Michael E.; Fitzner, Jeffrey N.; Stevens, Tracey; Chin, Wilson; Wright, Clifford D.; Boyce, Jim P.
CS Medicinal Chemistry, Amgen Inc., Seattle, WA, 98119, USA
SO Bioorganic & Medicinal Chemistry (2008), 16(18), 8760-8764
CODEN: BMECEP; ISSN: 0968-0896
PB Elsevier Ltd.
DT Journal
LA English
OS CASREACT 149:548243
AB Interleukin (IL)-12p40, a subunit component of both IL-12 and IL-23, is being widely studied for its role in inflammatory disease. As part of an effort to profile cellular signaling pathways across different cell types,

the authors report salicylanilide inhibitors of IL-12p40 production in stimulated dendritic cells. Based on a hypothesis that a desirable therapeutic profile is one that could block IL-12p40 but not IL-6 production, the authors engaged in directed analoging. This resulted in salicylanilides with similar IL-12p40 related potency but enhanced selectivity relative to IL-6 production

OSC.G 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)
RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2010 ACS on STN
TI Identification of 14-3-3ζ by Chemical Affinity with Salicylanilide Inhibitors of Interleukin-12p40 Production
AN 2008:1058126 CAPLUS <<LOGINID::20100726>>
DN 149:419458
TI Identification of 14-3-3ζ by Chemical Affinity with Salicylanilide Inhibitors of Interleukin-12p40 Production
AU Boyce, Jim P.; Brown, Michael E.; Chin, Wilson; Fitzner, Jeffrey N.; Paxton, Raymond J.; Shen, Min; Stevens, Tracey; Wolfson, Martin F.; Wright, Clifford D.
CS Amgen Incorporated, Seattle, WA, 98119, USA
SO Bioconjugate Chemistry (2008), 19(9), 1775-1784
CODEN: BCCHES; ISSN: 1043-1802
PB American Chemical Society
DT Journal
LA English
OS CASREACT 149:419458
AB Salicylanilides were found as selective inhibitors of interleukin-12p40 production in stimulated dendritic cells. The conversion of one of these bioactive salicylanilides into a comparably bioactive, chemical labeled derivative was achieved using a facile and systematic functional group derivatization strategy. This resulted in a tool reagent that was then employed in an affinity chromatog. approach that resulted in the identification of the protein 14-3-3ζ as having selective affinity for the chromatog. matrix that was derivatized with a salicylanilide that inhibited IL-12p40 production

OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2010 ACS on STN
TI Preparation of heterocyclic condensed compounds useful as antidiuretic agents
AN 2006:167754 CAPLUS <<LOGINID::20100726>>
DN 144:254156
TI Preparation of heterocyclic condensed compounds useful as antidiuretic agents
IN Pitt, Gary Robert William
PA Ferring B.V., Neth.
SO PCT Int. Appl., 85 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006018443	A1	20060223	WO 2005-EP54081	20050818

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,

NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM

				EP 2004-104006	A 20040820
				US 2004-602890P	P 20040820
EP 1627876		A1	20060222	EP 2004-104006	20040820

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR

AU 2005273875		A1	20060223	AU 2005-273875	20050818
AU 2005273875		B2	20090827		
				EP 2004-104006	A 20040820
				US 2004-602890P	P 20040820
				WO 2005-EP54081	W 20050818
CA 2567782		A1	20060223	CA 2005-2567782	20050818
				EP 2004-104006	A 20040820
				US 2004-602890P	P 20040820
				WO 2005-EP54081	W 20050818
EP 1778677		A1	20070502	EP 2005-781746	20050818
EP 1778677		B1	20100203		

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR

				EP 2004-104006	A 20040820
				US 2004-602890P	P 20040820
				WO 2005-EP54081	W 20050818
CN 1968947		A	20070523	CN 2005-80019297	20050818
				EP 2004-104006	A 20040820
				US 2004-602890P	P 20040820
				WO 2005-EP54081	W 20050818
JP 2008509972		T	20080403	JP 2007-526462	20050818
				EP 2004-104006	A 20040820
				US 2004-602890P	P 20040820
				WO 2005-EP54081	W 20050818
RU 2359969		C2	20090627	RU 2007-101237	20050818
				EP 2004-104006	A 20040820
				US 2004-602890P	P 20040820
				WO 2005-EP54081	W 20050818
AT 457026		T	20100215	AT 2005-781746	20050818
				EP 2004-104006	A 20040820
				US 2004-602890P	P 20040820
				WO 2005-EP54081	W 20050818
PT 1778677		E	20100317	PT 2005-781746	20050818
				EP 2004-104006	A 20040820
				US 2004-602890P	P 20040820
ES 2339786		T3	20100525	ES 2005-781746	20050818
				EP 2004-104006	A 20040820
				US 2004-602890P	P 20040820
IN 2006DN06342		A	20070831	IN 2006-DN6342	20061027
				US 2004-602890P	P 20040820
				WO 2005-EP54081	W 20050818
KR 20070027761		A	20070309	KR 2007-702387	20070130
KR 877336		B1	20090107		
				EP 2004-104006	W 20040820
				US 2004-602890P	P 20040820
				WO 2005-EP54081	W 20050818
MX 2007001861		A	20070424	MX 2007-1861	20070215
				EP 2004-104006	A 20040820

			US 2004-602890P	P	20040820
			WO 2005-EP54081	W	20050818
US 20080234250	A1	20080925	US 2008-660207		20080516
			EP 2004-104006	A	20040820
			US 2004-602890P	P	20040820
			WO 2005-EP54081	W	20050818

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS CASREACT 144:254156; MARPAT 144:254156

GI



I



II

AB The title compds. I [W = N, CR4; X = O, S, C(O), etc.; G1 = bicyclic or tricyclic fused azepine; R1, R2 = H, halo, alkyl, etc.; R3 = H, alkyl; R4-R7 = H, halo, alkyl, etc.; a = 1-3] which are vasopressin V2 receptor agonists, were prepared and formulated. E.g., a multi-step synthesis of II, starting from 1,2-difluoro-3-nitrobenzene and β-alanine Me ester hydrochloride, was given. V2 receptor agonist activity was determined for all compds. and all the compds. I cause significant cellular activation at 30 μM or less. Pharmaceutical compns. of the compds. I are useful as antidiuretic agents.

OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2010 ACS on STN

TI Compounds and compositions as LXR modulators

AN 2005:902755 CAPLUS <<LOGINID::20100726>>

DN 143:242051

TI Compounds and compositions as LXR modulators

IN Molteni, Valentina; Li, Xiaolin; Liang, Fang; Nabakka, Juliet; Saez, Enrique; Wityak, John

PA IRM LLC, Bermuda

SO PCT Int. Appl., 51 pp.
CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	WO 2005077122	A2	20050825	WO 2005-US4652		20050211
	WO 2005077122	A3	20051229			
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM					
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
				US 2004-544149P	P	20040211
	AU 2005211807	A1	20050825	AU 2005-211807		20050211
	AU 2005211807	B2	20080828			
				US 2004-544149P	P	20040211
				WO 2005-US4652	W	20050211
	CA 2553442	A1	20050825	CA 2005-2553442		20050211
				US 2004-544149P	P	20040211
				WO 2005-US4652	W	20050211
	EP 1713465	A2	20061025	EP 2005-723051		20050211
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS					
				US 2004-544149P	P	20040211
				WO 2005-US4652	W	20050211
	CN 1917870	A	20070221	CN 2005-80004674		20050211
				US 2004-544149P	P	20040211
				WO 2005-US4652	W	20050211
	BR 2005007626	A	20070703	BR 2005-7626		20050211
				US 2004-544149P	P	20040211
				WO 2005-US4652	W	20050211
	JP 2007523087	T	20070816	JP 2006-553323		20050211
				US 2004-544149P	P	20040211
				WO 2005-US4652	W	20050211
	IN 2006CN02907	A	20070608	IN 2006-CN2907		20060808
				US 2004-544149P	P	20040211
				WO 2005-US4652	W	20050211
	MX 2006009159	A	20061110	MX 2006-9159		20060811
				US 2004-544149P	P	20040211
				WO 2005-US4652	W	20050211
	US 20070293547	A1	20071220	US 2007-589410		20070604
				US 2004-544149P	P	20040211
				WO 2005-US4652	W	20050211

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS MARPAT 143:242051
AB The invention provides compds., pharmaceutical compns. comprising such compds. and methods of using such compds. to treat or prevent diseases or disorders associated with the activity of liver X receptors (LXRs).
OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2010 ACS on STN
TI Preparation of 2-[(carbamoylmethyl)carbamoyl]phenylpropanoates and analogs as αvβ3 integrin receptor ligands

AN 2002:484686 CAPLUS <<LOGINID::20100726>>
DN 137:47124
TI Preparation of 2-[(carbamoylmethyl)carbamoyl]phenylpropanoates and analogs as αvβ3 integrin receptor ligands
IN Geneste, Herve; Kling, Andreas; Lange, Udo; Lauterbach, Arnulf; Seitz, Werner; Graef, Claudia Isabella; Subkowski, Thomas; Hornberger, Wilfried; Kluge, Michael; Spriesterbach, Rainer
PA Knoll A.-G., Germany
SO Ger. Offen., 62 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DE 10064823	A1	20020627	DE 2000-10064823	20001222
WO 2002051810	A2	20020704	WO 2001-EP14924	20011218
WO 2002051810	A3	20030320		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

			DE 2000-10064823	A 20001222
AU 2002240846	A1	20020708	AU 2002-240846	20011218
			DE 2000-10064823	A 20001222
			WO 2001-EP14924	W 20011218

OS MARPAT 137:47124
GI



I

AB Title compds. were prepared as αvβ3 integrin receptor ligands (no data). Thus, 2-(OHC)C6H4CO2H was condensed with (EtO)2P(O)CH2CO2Me and the hydrogenated product amidated by MeNHCH2CO2CMe3 to give, after saponification, 2-(HO2CH2CH2C)C6H4CONMeCH2CO2H which was amidated by N-(2-pyridinyl)ethandiamine to give, after saponification, title compound I.

L4 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2010 ACS on STN
TI Preparation of guanidinophenol derivatives as phospholipase and trypsin inhibitors
AN 1994:217002 CAPLUS <<LOGINID::20100726>>
DN 120:217002
OREF 120:38505a,38508a

TI Preparation of guanidinophenol derivatives as phospholipase and trypsin inhibitors
IN Nakai, Hisao; Kawamura, Masanori; Myamoto, Tsumoru
PA Ono Pharmaceutical Co, Japan
SO Jpn. Kokai Tokkyo Koho, 18 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 05286922	A	19931102	JP 1992-116657	19920410
JP 3220225	B2	20011022		
			JP 1992-116657	19920410

OS MARPAT 120:217002
GI



I



II



III



IV

AB The title compds. I (R = alkyl, alkoxy, CO2R1, etc.; R1 = H, alkyl) were prepared Condensation of carboxylic acid II and phenol III.HCl in pyridine containing DCC gave, after workup, title compound IV.HCl. Compds. I in vitro exhibited IC50 values of 2.4 - 44 μM against phospholipase A2. A formulation containing I is given.

L4 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2010 ACS on STN
TI Benzoylglycine derivatives as herbicides and their preparation
AN 1989:75068 CAPLUS <<LOGINID::20100726>>
DN 110:75068
OREF 110:12389a,12392a
TI Benzoylglycine derivatives as herbicides and their preparation
IN Hopwood, William John
PA Shell Internationale Research Maatschappij B. V., Neth.
SO Eur. Pat. Appl., 36 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 280367	A2	19880831	EP 1988-200295	19880217
EP 280367	A3	19900523		
EP 280367	B1	19931103		

R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE

			GB 1987-4671	A	19870227
AT 96776	T	19931115	AT 1988-200295		19880217
			GB 1987-4671	A	19870227
			EP 1988-200295	A	19880217
AU 8812190	A	19880901	AU 1988-12190		19880225
AU 611413	B2	19910613			
			GB 1987-4671	A	19870227
CN 88100995	A	19880907	CN 1988-100995		19880225
CN 1017799	B	19920812			
			GB 1987-4671	A	19870227
JP 63227555	A	19880921	JP 1988-40932		19880225
			GB 1987-4671	A	19870227
BR 8800793	A	19881004	BR 1988-793		19880225
			GB 1987-4671	A	19870227
ZA 8801330	A	19881026	ZA 1988-1330		19880225
			GB 1987-4671	A	19870227
IL 85547	A	19930610	IL 1988-85547		19880225
			GB 1987-4671	A	19870227
US 5110348	A	19920505	US 1990-548190		19900705
			GB 1987-4671	A	19870227
			US 1988-150989	B1	19880201

OS MARPAT 110:75068

AB The title compds. XN(COY)CH2COLZ [I; X = Ph substituted in the 2-position and optionally substituted in other positions; Y = (substituted) Ph; L = O, S; Z = H, (substituted) alkyl, cycloalkyl, alkenyl, alkynyl, etc.] and salts were prepared as herbicides. A mixture of 2-cyanoaniline, BrCH2CO2Et, and NaHCO3 in EtOH was refluxed for 42 h to give N-(2-cyanophenyl)glycine Et ester, which reacted with BzCl in refluxing xylene to give N-benzoyl-N-2-cyanophenylglycine Et ester (II). In a pre-emergence test, II at 5 kg/ha gave 77% control of barnyard grass.

OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

=> logoff hold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	31.42	224.16

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-6.80	-6.80

SESSION WILL BE HELD FOR 120 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 05:45:00 ON 26 JUL 2010